MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
WALTHAM, Mass., Feb. 28, 2018 -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced its support for the patient and research communities in recognition of Rare Disease Day 2018.
“At Chiasma, we are focused on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases,” said Mark Fitzpatrick, president and CEO of Chiasma. “The theme for Rare Disease Day 2018 is ‘research’ – and for good reason. Last year, rare or orphan disease treatments accounted for nearly 40% of all new drugs approved by the FDA -- all to the benefit of the patients and their families who desperately need treatments. For this reason, we also pay tribute to the patient community, which makes our drug development efforts so meaningful. We strongly believe in our own mission, to enhance the lives of adult patients living with acromegaly, and we join with policy makers, researchers, companies and healthcare professionals in the drive to increasingly and more effectively involve patients in rare disease research.”
Rare Disease Day takes place on the last day of February each year. The main objective is to raise awareness among the general public and decision-makers about rare diseases and their impact on patients' lives. For more information about Rare Disease Day, please visit www.rarediseaseday.org.
About Chiasma
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. The Company recently initiated CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated following SPA agreement with the FDA on the design of the trial. Chiasma is headquartered in Waltham, MA with a wholly owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at www.chiasma.com.
Contact:
Andrew Blazier
Sharon Merrill Associates
(617) 542-5300
[email protected]
